Low‐dose IL‐2 induces CD56bright NK regulation of T cells via NKp44 and NKp46
Low‐dose interleukin (IL)‐2 has shown clinical benefits in patients with autoimmune and inflammatory diseases. Both regulatory T cells (Tregs) and natural killer (NK) cells are increased in response to low‐dose IL‐2 immunotherapy. The role of regulatory T cells in autoimmune diseases has been extensively studied; however, NK cells have not been as thoroughly explored. It has not been well reported whether the increase in NK cells is purely an epiphenomenon or carries actual benefits for patients with autoimmune diseases. We demonstrate that low‐dose IL‐2 expands the primary human CD56bright NK cells resulting in a contact‐dependent cell cycle arrest of effector T cells (Teffs) via retention of the cycle inhibitor p21. We further show that NK cells respond via IL‐2R‐β, which has been shown to be significant for immunity by regulating T cell expansion. Moreover, we demonstrate that blocking NK receptors NKp44 and NKp46 but not NKp30 could abrogate the regulation of proliferation associated with low‐dose IL‐2. The increase in NK cells was also accompanied by an increase in Treg cells, which is dependent on the presence of CD56bright NK cells. These results not only heighten the importance of NK cells in low‐dose IL‐2 therapy but also identify key human NK targets, which may provide further insights into the therapeutic mechanisms of low‐dose IL‐2 in autoimmunity.